Algorithm for monitoring patients with axial spondyloarthritis depending on the activity of the disease
https://doi.org/10.14412/1996-7012-2025-1-72-75
Abstract
Axial spondyloarthritis (axSpA) is actively treated with biologic disease-modifying antirheumatic drugs, but their efficacy decreases over time, leading to the development of exacerbation, the onset of severe and chronic pain, progression of structural changes and deterioration of quality of life, as well as significant economic losses. The international community is increasingly concerned about the problem of identifying difficultto-treat (D2T) patients. In this context, it is necessary to develop strategies and markers for their identification and effective treatment. The authors propose a regimen of follow-up that represents an innovative approach to monitoring patients with D2T axSpA.
About the Authors
A. V. Datsina
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
Anastasia Valerievna Datsina,
34A, Kashirskoe Shosse, Moscow 115522
Sh. F. Erdes
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
References
1. The Lancet. A platinum age for rheumatology. Lancet. 2017 Jun 10;389(10086):2263. doi: 10.1016/S0140-6736(17)31577-5.
2. Philippoteaux C, Delepine T, Cailliau E, et al.Characteristics of difficult-to-treat axial spondyloarthritis: Results of a real-world multicentric study. Joint Bone Spine. 2024 Mar; 91(2):105670. doi: 10.1016/j.jbspin.2023.105670.
3. Mease PJ. Fibromyalgia, a missed comorbidity in spondyloarthritis: prevalence and impact on assessment and treatment. Curr Opin Rheumatol. 2017 Jul;29(4):304-310. doi: 10.1097/BOR.0000000000000388.
4. Baraliakos X, Kiltz U, Peters S, et al. Efficiency of treatment with non-steroidal antiinflammatory drugs according to current recommendations in patients with radiographic and non-radiographic axial spondyloarthritis. Rheumatology (Oxford). 2017 Jan; 56(1):95- 102. doi: 10.1093/rheumatology/kew367.
5. Winthrop KL, Mease P, Kerschbaumer A, et al. Unmet need in rheumatology: reports from the Advances in Targeted Therapies meeting, 2023. Ann Rheum Dis. 2024 Mar 12;83(4):409-416. doi: 10.1136/ard-2023-224916.
6. Erdes ShF, Sakharova KV, Dubinina TV, Cherkasova MV. Clinical features of patients with ankylosing spondylitis with inefficacy of two or more biological disease modifying antirheumatic drugs. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2023;17(3): 30-36. (In Russ.). doi: 10.14412/1996-7012-2023-3-30-36.
7. Danve A. Deodhar. Treatment of axial spondyloarthritis: an update. Nat Rev Rheumatol. 2022 Apr;18(4):205-216. doi: 10.1038/s41584-022-00761-z.
8. Lindström U, Olofsson T, Wedren S, et al. Biological treatment of ankylosing spondylitis: a nationwide study of treatment trajectories on a patient level in clinical practice. Arthritis Res Ther. 2019 May 28; 21(1):128. doi: 10.1186/s13075-019-1908-9.
9. Navarro-Compan V, Sepriano A, El-Zorkany B, et al. Axial spondyloarthritis. Ann Rheum Dis. 2021 Dec;80(12):1511-1521. doi: 10.1136/annrheumdis-2021-221035.
10. Roodenrijs NMT, Welsing PMJ, van der Goes MC, et al. Healthcare utilization and economic burden of difficult-to-treat rheumatoid arthritis: a cost-of-illness study. Rheumatology (Oxford). 2021 Oct 2;60(10): 4681-4690. doi: 10.1093/rheumatology/keab078.
11. Molto A, Lopez-Medina C, van den Bosch FE, et al. Efficacy of a tightcontrol and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial. Ann Rheum Dis. 2021 Nov;80(11):1436- 1444. doi: 10.1136/annrheumdis-2020-219585.
12. Parigi TL, D'Amico F, Abreu MT, et al. Difficulttotreat inflammatory bowel disease: results from a global IOIBD survey. Lancet Gastroenterol Hepatol. 2022 May;7(5):390- 391. doi: 10.1016/S2468-1253(22)00085-1.
13. Nagy G, Roodenrijs NMT, Welsing PMJ , et al. EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis. Ann Rheum Dis. 2022 Jan;81(1):20- 33. doi: 10.1136/annrheumdis-2021-220973.
14. Lubrano E, Scriffignano S, Perrotta FM. Difficult to treat and refractory to treatment in psoriatic arthritis. Rheumatol Ther. 2023 Oct;10(5):1119-1125. doi: 10.1007/s40744-023-00574-w.
15. Wendling D, Verhoeven F, Prati C, et al. Is the difficult-to-treat (D2T) concept applicable to axial spondyloarthritis? Joint Bone Spine. 2023 Mar;9(1):e002842. doi: 10.1136/rmdopen-2022-002842.
16. Giuseppe D Di, Lindström U, Aaltonen K, et al. The occurrence of multiple treatment switches in axial spondyloarthritis. Results from five Nordic rheumatology registries. Rheumatology (Oxford). 2022 Aug 30;61(9): 3647-3656. doi: 10.1093/rheumatology/keab946.
17. Fakih O, Desmarets M, Martin B, et al. Difficult-to-treat axial spondyloarthritis is associated with psoriasis, peripheral involvement and comorbidities: results of an observational nationwide study. RMD Open. 2023 Nov 23;9(4):e003461. doi: 10.1136/rmdopen2023-003461.
18. Dua D, Blake T. Difficult to treat spondyloarthritis: patients with a high biologic switch rate and the factors influencing it; a real world as clinic experience. https://acrabstracts.org/abstract/difficult-to-treat-spondyloarthritispatients-with-a-high-biologic-switch-rateand-the-factors-influencing-it-a-real-worldas-clinic-experience/
19. ASAS definition of difficult-to-treat axial spondyloarthritis. https://www.asas-group.org/asas-definition-of-difficult-to-treataxial-spondyloarthritis/
20. Maneiro JR, Souto A, Salgado E, et al. Predictors of response to TNF antagonists in patients with ankylosing spondylitis and psoriatic arthritis: systematic review and metaanalysis. RMD Open. 2015 Feb 18;1(1): e000017. doi: 10.1136/rmdopen-2014-000017.
21. Zhao SS, Jones GT, Macfarlane GJ, et al. Comorbidity and response to TNF inhibitors in axial spondyloarthritis: longitudinal analysis of the BSRBR-AS. Rheumatology (Oxford). 2021 Sep 1;60(9):4158-4165. doi: 10.1093/rheumatology/keaa900.
22. Krabbe S, Glintborg B, Ostergaard M, et al. Extremely poor patient-reported outcomes are associated with lack of clinical response and decreased retention rate of tumour necrosis factor inhibitor treatment in patients with axial spondyloarthritis. Scand J Rheumatol. 2019 Mar;48(2):128-132. doi: 10.1080/03009742.2018.1481225. Epub 2018 Aug 13.
23. Glintborg B, Ostergaard M, Krogh NS, et al. Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years’ surveillance in the Danish nationwide DANBIO registry. Ann Rheum Dis. 2010 Nov;69(11): 2002-8. doi: 10.1136/ard.2009.124446. Epub 2010 May 28.
24. Van Der Heijde D, Ramiro S, Landewe R, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017 Jun; 76(6):978-991. doi: 10.1136/annrheumdis2016-210770.
25. Kearsley-Fleet L, Davies R, De Cock D, et al. BSRBR-RA Contributors Group. Biologic refractory disease in rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Ann Rheum Dis. 2018 Oct;77(10):1405-1412. doi: 10.1136/annrheumdis-2018-213378. Epub 2018 Jul 6.
26. Rusman T, van Vollenhoven RF, van der Horst-Bruinsma IE. Gender differences in axial spondyloarthritis: women are not so lucky. Curr Rheumatol Rep. 2018 May 12;20(6):35. doi: 10.1007/s11926-018-0744-2.
27. Biallas RL, Dean LE, Davidson L, et al. The role of metrology in axSpA: does it provide unique information in assessing patients and predicting outcome? Results from the BSRBR-AS registry. Arthritis Care Res (Hoboken). 2022 Apr;74(4):665-674. doi: 10.1002/acr.24500.
Review
For citations:
Datsina AV, Erdes SF. Algorithm for monitoring patients with axial spondyloarthritis depending on the activity of the disease. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2025;19(1):72-75. https://doi.org/10.14412/1996-7012-2025-1-72-75
Views:
738
Email this article 